Results 91 to 100 of about 4,708 (131)

Weight gain on tenofovir alafenamide fumarate-based therapy compared to tenofovir disoproxil fumarate- and abacavir-based therapy in children and young people living with HIV in Europe. [PDF]

HIV Med
European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) Study Group.
europepmc   +1 more source

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate Regimen and Its Effect on Liver Steatosis Assessed by Fibroscan. [PDF]

Viruses
Trizzino M, Gaudiano R, Arena DM, Pipitò L, Gioè C, Cascio A.   +5 more
europepmc   +1 more source

Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial. [PDF]

BMJ Open, 2021
Wang L, Wu L, Li X, Zhang Y, Lai J, Zhu X, Xie C, Peng L.   +7 more
europepmc   +1 more source

Switch to Fixed Dose of Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate Versus Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate in Virologically Suppressed Adults on Efavirenz-Based Regimens: 48-Week Results of a Real-world, Prospective, Observational Cohort Study. [PDF]

Open Forum Infect Dis
Li A, Li Z, Li J, Gao Y, Dai L, Liu A, Zhang H, Wang X, Wu L, Yao Y, Liu L, Ye J, Sun L.   +12 more
europepmc   +1 more source

Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort. [PDF]

Eur J Hosp Pharm, 2023
Rotea-Salvo S, Martínez-Pradeda A, Fernández-Oliveira C, Giménez-Arufe V, Balboa-Barreiro V, Margusino-Framiñán L, Mena-De-Cea Á, Vázquez-Rodríguez P, Castro-Iglesias Á, López-Calvo S, Martín-Herranz I, Míguez-Rey E, Cid-Silva P.   +12 more
europepmc   +1 more source

Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B. [PDF]

Virol J
Cao F, Fan T, Jiang X, Wang J, Liu Y, Zhu L, Xiong Y, Zhang S, Zhang Z, Pan Y, Li Y, Jiang C, Xia J, Yan X, Li J, Liu X, Zhu C, Huang R, Wu C.   +18 more
europepmc   +1 more source

Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma. [PDF]

Antimicrob Agents Chemother, 2020
Parsons TL, Gwenden KN, Marzinke MA.
europepmc   +1 more source

Effect of Tenofovir Alafenamide Fumarate on the outcomes of hospitalized COVID-19 patients: a prospective, block-balanced, open-label, randomized controlled trial. [PDF]

BMC Pharmacol Toxicol
Yazdan Pouri N, Shokati Eshkiki Z, Talebi A, Cheraghian B, Ahmadi F, Neisi N, Shayesteh AA.   +6 more
europepmc   +1 more source

Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum. [PDF]

Clin Infect Dis
Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S, IMPAACT 2010/VESTED Study Team.   +28 more
europepmc   +1 more source

Relationship between adherence to bictegravir/emtricitabine/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis. [PDF]

Sci Rep
Taguchi N, Piao Y, Rubino A, Lee K, Chen M, Harada K, Tanikawa T, Naito T.   +7 more
europepmc   +1 more source